The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Novo Nordisk has announced plans to invest DKK 500 million ($82 million) to expand table production facilities at its site in Måløv, Denmark.
The facility currently manufactures products for oral diabetes treatment and will be expanded to ensure...
Merck & Co. has agreed to acquire Pandion Therapeutics, a Watertown, Massachusetts-based company developing therapeutics for autoimmune diseases, for an approximate total equity value of $1.85 billion.
Pandion is advancing a pipeline of...
A roundup of news from Canada (Bausch Health, Novo Nordisk), Germany (Merck KGaA), and the US (Pfizer, AstraZeneca, AbbVie, Lilly, UCB, and Century Therapeutics).
Canada
Bausch Health To Reduce Debt By $100 M Bausch Health Companies (formerly...
Sanofi has entered into an agreement with Janssen Pharmaceutical NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson (J&J), to support the manufacturing of J&J’s single-dose COVID-19...
Bristol-Myers Squibb (BMS) has announced that construction is underway for a new cell-therapy manufacturing facility at its biomanufacturing site in Devens, Massachusetts.
The new cell-therapy facility will be located on BMS’s current 89-acre...
AstraZeneca’s COVID-19 vaccine has been granted emergency use listing (EUL) by the World Health Organization (WHO) and provisional approval by Australia’s Therapeutic Goods Administration (TGA), the national pharmaceutical regulatory agency in...
The US government reported last week (February 11, 2020) that it had purchased an additional 100 million doses each of the COVID-19 vaccines respectively by Pfizer/BioNTech and Moderna.
The orders placed bring the vaccine purchased by the US...
A roundup of news from China (AstraZeneca), Switzerland (Novartis), and the US (IFF, DuPont, Sanofi, Regeneron, Fresenius Kabi, Mallinckrodt, and bluebird bio).
China
AstraZeneca, Hong Kong Launch Biomedical Oncology Co-Incubation Program...
The latest on manufacturing, potential treatments, and testing for COVID-19 with news from J&J, GSK, Vir Biotechnology, Novavax, CureVac, Thermo Fisher, and BD.
Manufacturing and supply of COVID-19 vaccines and drugs
Novavax, SK Bioscience...
Eli Lilly and Company and Rigel Pharmaceuticals, a South San Francisco, California-based biopharmaceutical company, have entered into a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a...
A roundup of news from Japan (Bristol-Myers Squibb), the UK (AstraZeneca), and the US (Pfizer, Apotex, AbbVie, Gilead, Caribou Biosciences, and Jubilant).
Japan
BMS Donates $52 M for Cancer Research in Japan Bristol-Myers Squibb has donated JPY...
The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for Eli Lilly and Company’s investigational combination therapy for the treatment of COVID-19, bamlanivimab (700 mg) and etesevimab (1,400 mg).
This therapy is...
BioNTech, a Mainz, Germany-based immunotherapy company, is increasing production at its site in Marburg, Germany as part of a plan by Pfizer/BioNTech to increase global production of their COVID-19 vaccine from 1.3 billion doses to 2 billion...
The latest on manufacturing, potential treatments/vaccines, and testing for COVID-19 with news from J&J, Moderna, Thermo Fisher, Novavax, CureVac, Sinovac, and Celltrion.
Manufacturing and supply of COVID-19 vaccines and drugs
Moderna in...
AstraZeneca has added two additional manufacturing partners for its COVID-19 vaccine, respectively in Japan and Europe, with Daiichi Sankyo and IDT Biologika, a Dessau-Rosslau, Germany-based CDMO. Also, the South African government suspended the...
